U.S. Most-Favoured-Nation policy impacts global pharmaceutical markets

The United States' Most-Favoured-Nation (MFN) policy is reshaping the global pharmaceutical market by attempting to link U.S. drug prices to those paid in other wealthy nations. This policy functions as a suite of pricing, trade, and industrial instruments designed to exert price pressure while simultaneously incentivizing pharmaceutical production and research activities to move to the U.S.

While not directly targeting Poland, the policy may have indirect consequences due to the interconnected nature of European reference pricing. Pharmaceutical manufacturers may alter the timing of new therapy launches, limit indications, or seek confidential risk-sharing agreements to avoid low prices in smaller markets that could trigger broader revenue reductions.

A potential transmission channel exists through regional dependencies; for example, the Czech Republic's pricing system may use Polish prices as a benchmark. Furthermore, while Poland remains outside the primary scope of the proposed U.S. GLOBE basket, the Czech Republic has been included, creating complex cross-border economic implications.